Properties (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:antiSubmarineWarfare |
debates on access
|
| gptkbp:approves |
gptkb:FDA
EMA |
| gptkbp:brand |
Comirnaty
|
| gptkbp:clinicalTrials |
44,000
Phase 3 trials Phase 1/2/3 |
| gptkbp:communityPartnerships |
gptkb:COVAX
|
| gptkbp:contraindication |
fatigue
headache muscle pain fever chills |
| gptkbp:developedBy |
gptkb:Pfizer
gptkb:BioNTech |
| gptkbp:diseaseResistance |
published in medical journals
|
| gptkbp:dosageForm |
two doses
|
| gptkbp:evaluates |
95% in preventing COVID-19
|
| gptkbp:expansion |
recommended after 6 months
|
| gptkbp:firstAppearance |
December 11, 2020
|
| gptkbp:foughtAgainst |
global vaccination efforts
|
| gptkbp:hasAuthorityOver |
December 2020
|
| gptkbp:hasResearchInterest |
variant-specific vaccines
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pfizer-BioNTech
|
| gptkbp:incubationPeriod |
significant in pandemic control
|
| gptkbp:isSubjectTo |
1 month at 2-8°C
6 months at -70°C |
| gptkbp:marketedAs |
over 100 countries
|
| gptkbp:notable_player |
varies by country
global distribution emergency use authorization intramuscular injection ongoing studies widely accepted preventive vaccine ultra-cold freezers government and private funding against variants community immunity reduction in deaths reduction in hospitalizations WHO approval mRNA technology advancement |
| gptkbp:partnerships |
Pfizer_and_BioNTech
|
| gptkbp:produces |
gptkb:Germany
gptkb:USA |
| gptkbp:providesSupportFor |
gptkb:US_government
EU_government |
| gptkbp:researchInterest |
mRNA technology
|
| gptkbp:safetyFeatures |
gptkb:VAERS
|
| gptkbp:storage |
-70°C
|
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:technology |
lipid nanoparticles
|
| gptkbp:type |
mRNA vaccine
|
| gptkbp:updates |
new formulations
|